Headquartered in North Chicago, IL Fiscal year ends December NYSE: ABBV abbvie.com
AbbVie is a global biopharmaceutical company focused on discovering and delivering innovative medicines across several key therapeutic areas, including immunology, neuroscience, and oncology, as well as aesthetics products and services through its Allergan Aesthetics portfolio. Its immunology franchise is anchored by Skyrizi (risankizumab) and Rinvoq (upadacitinib), which have become major growth drivers as the legacy Humira (adalimumab) franchise faces biosimilar competition. In neuroscience, the company markets Vraylar (cariprazine) for psychiatric disorders, Botox Therapeutic for neurological conditions, and migraine treatments Ubrelvy and Qulipta, along with Vyalev for Parkinson's disease. The oncology portfolio includes Venclexta (venetoclax) for hematologic malignancies, Imbruvica (ibrutinib) for blood cancers, Elahere for ovarian cancer, and the bispecific antibody Epkinly (epcoritamab) co-developed with Genmab for lymphoma. The aesthetics business encompasses Botox Cosmetic, the Juvederm Collection of dermal fillers, and the newly approved rapid-onset neurotoxin Boey. AbbVie is actively expanding its pipeline through acquisitions, including the pending acquisition of Apogee Therapeutics to deepen its immunology portfolio with novel IL-13 and TSLP-targeting therapies for atopic dermatitis and asthma. Updated
A 3.1% slide to $273.85 lands minutes after new Phase 3 AFFIRM data for subcutaneous Skyrizi in Crohn's disease hit the wire. Skyrizi is the growth engine meant to carry the post-Humira era, so the market's read on this data matters.
AbbVie set a fresh 52-week high at $272.42, the second straight day of records for the drugmaker. Keep an eye on whether it holds.
AbbVie cleared its August record with a fresh 52-week high at $266.28, 0.12% above the prior peak, on the same day it announced FDA approval of JUVMO. A $470.9 billion pharma making new highs is a momentum signal income investors rarely get.
Sessions dumped a big pharma name and Alphabet on the same day, then filed within four days, an unusually fast turnaround that pins down the timing. Paired healthcare and megacap tech selling from a sitting House member is a signal to catch before the next leg of either trade.
Six names hit fresh 52-week highs this week: SentinelOne led at 6.14% above its prior peak, with Coca-Cola, Expedia, Airbnb, AbbVie and Pfizer all clearing old ceilings too.
AbbVie touched a new 52-week high at $265.97, clearing its July 29 peak. The $470 billion pharma has left its spring range near $200 behind.
Two of these five dividend stocks just took a beating in October, and that selloff quietly pushed their yields to levels that make the safer-looking names on the list look stingy by…
Eli Lilly trades at a premium multiple, yet its revenue growth dwarfs every major pharma peer by a wide margin. Whether that gap justifies buying shares near all-time highs depends on one…
Skyrizi and Rinvoq are growing fast, a blockbuster acquisition just closed, and the FDA handed AbbVie a fresh approval, yet the stock sits just shy of a price target that has Wall…
A 5% Treasury yield raises the bar for every dividend stock in a retirement portfolio, and not every high-yielder clears it. These five names span telecom, real estate, consumer staples, utilities, and…
Three of these six income stocks beat current Treasury bill yields, but a higher number on the label does not settle the argument once taxes, reinvestment risk, and dividend safety enter the…
Cantor Fitzgerald just bumped price targets on Eli Lilly, AbbVie, Merck, and Pfizer, but higher targets do not mean equal conviction. The firm's split between Overweight and Neutral ratings reveals a sharp…
A fat dividend yield means nothing if the cash runs dry before the check clears. These five companies show wildly different margins of safety, and one of them barely cleared the bar…
Johnson & Johnson just logged its 64th straight year of dividend growth, but biosimilar threats, a MedTech slowdown, and lingering talc litigation raise a real question about whether that streak justifies buying…
Treasuries now offer a yield that dividend investors once bragged about, which raises a question most retirees avoid asking: does an equity income portfolio actually come out ahead after risk, taxes, and…
The 24/7 Wall St. price target for Eli Lilly (NYSE:LLY | LLY Price Prediction) is $1,359.12 over the next 12 months. With the stock at $1,142.85, that implies 18.92% upside. Lilly wins…
When paychecks stop, the wrong income strategy forces you to sell shares at the worst possible moment. Five companies have raised their dividends through every recession and rate shock in modern memory,…
AbbVie investors who bought on headline-grabbing drug approvals consistently trailed those who bought during fear and uncertainty. The calendar of milestones reveals a counterintuitive pattern about when good news becomes a trap.
Three blue-chip dividend stocks sitting in a taxable account hand a portion of every payout straight to the IRS, but the account type holding them changes that math completely. Here is what…
From a pharma giant rebuilding after a blockbuster patent loss to a pipeline partnership targeting double-digit distribution raises through 2027, these five stocks span wildly different industries yet share one thing: cash…
Replacing a $160,000 salary with dividends at 58 sounds like a single math problem, but the required portfolio swings by millions depending on which yield tier you choose, and the tier that…
AbbVie is a global biopharmaceutical company focused on discovering and delivering innovative medicines across several key therapeutic areas, including immunology, neuroscience, and oncology, as well as aesthetics products and services through its Allergan Aesthetics portfolio.
24/7 Wall St.'s 12-month price target for ABBV is $285.27, rated Hold. The Wall Street consensus target is $282.61. ABBV price prediction →
